Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
9vHPV Vaccine · 1 trial · 1 indication
GMTs for HPV were measured by immunoglobulin G binding assay (IgGBA) assay. HPV-6, HPV-11, HPV-16, HPV-18, HPV-31, HPV-33, HPV-45, HPV-52 and HPV-58 were the types of HPV analyzed.
| Arm | Type | Description |
|---|---|---|
| 9vHPV+TDV | EXPERIMENTAL | Participants will receive 0.5 mL 9vHPV intramuscularly (IM) with 0.5 mL TDV subcutaneously (SC) once on Day 1 (Month 0) followed by 0.5 mL TDV SC once on Day 90 (Month 3) and 0.5 mL 9vHPV IM once on Day 180 (Month 6). |
| 9vHPV | EXPERIMENTAL | Participants will receive 0.5 mL 9vHPV vaccine IM once on Day 1 (Month 0) followed by 0.5 mL 9vHPV vaccine IM once on Day 180 (Month 6). |
| Name | Type | Description |
|---|---|---|
| 9vHPV Vaccine | BIOLOGICAL | 9vHPV intramuscular injection |
| Dengue Tetravalent Vaccine (TDV) | BIOLOGICAL | TDV subcutaneous injection |
Inclusion Criteria: 1. Participants who are in good health at the time of entry into the trial as determined by medical history, physical examination (including vital signs), and the clinical judgment of the investigator. 2. Participants who can comply with trial procedures and are available for th...
9vHPV Vaccine is a recombinant 9-valent human papillomavirus vaccine being studied in participants aged 9 to under 15 years. It is being evaluated in a Phase 3 clinical trial for its immunogenicity and safety, with the trial also assessing a dengue tetravalent vaccine. The vaccine is intended for use in infectious disease prevention.
9vHPV Vaccine is developed by Takeda Pharmaceutical Company Limited, which trades under the ticker TAK. The company is conducting a Phase 3 clinical trial to evaluate the vaccine's immunogenicity and safety in participants aged 9 to under 15 years.
9vHPV Vaccine is in Phase 3 clinical development. It is an investigational vaccine, not yet approved, and is being studied in a completed Phase 3 trial (NCT04313244) that evaluated its immunogenicity and safety in 614 participants aged 9 to under 15 years.
9vHPV Vaccine is associated with one completed Phase 3 clinical trial, NCT04313244, titled 'Immunogenicity and Safety of Dengue Tetravalent Vaccine (TDV) and Recombinant 9-valent Human Papillomavirus Vaccine (9vHPV) in Participants Aged ≥9 to <15 Years'. The trial enrolled 614 participants in Thailand and was controlled but not double-blind.
No, 9vHPV Vaccine is a recombinant 9-valent human papillomavirus vaccine, not a dengue vaccine. It was studied alongside a dengue tetravalent vaccine in the same clinical trial, NCT04313244, which evaluated both vaccines' immunogenicity and safety in participants aged 9 to under 15 years.